SANOFI · Healthcare · Drug Manufacturers - General
Composite scorecard: 59/100 — Quality 91 · Valuation 49 · Momentum 0
| Share price | ₹3,391.80 |
| Market cap | ₹7,835 Cr |
| P/E ratio | 25.3 |
| P/B ratio | 10.5 |
| ROE | 92.0% |
| ROCE | 58.5% |
| Dividend yield | 7.05% |
| Book value | ₹325.31 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2025 | ₹2,013 Cr | ₹413 Cr | 24.0% |
| 2024 | ₹1,996 Cr | ₹603 Cr | 24.0% |
| 2023 | ₹1,982 Cr | ₹603 Cr | 22.9% |
| 2022 | ₹2,727 Cr | ₹621 Cr | 24.4% |
| 2021 | — | — | — |
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as